Cellid, Co., Ltd.
299660.KQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$55.52B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $55.52 Billion |
|---|---|
| Enterprise Value | $76.37 Billion |
| Earnings per Share | $-409.08 |
| Beta | 0.44 |
| Outstanding Shares | 29,502,977 |
Return
| Return on Equity | -51.02% |
|---|---|
| Return on Assets | -28.28% |
| Return on Invested Capital | -17.57% |
Valuation & Multiples
| P/E Ratio | -2.03 |
|---|---|
| PEG | -0.31 |
| Price to Sales | 5.07 |
| Price to Book Ratio | 0.98 |
| Enterprise Value to Revenue | 7.33 |
| Enterprise Value to EBIT | -7.13 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.44 |
| Debt to Equity | 0.63 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cellid, Co., Ltd.
49 employees
CEO: Yuil Kang Chang
Cellid, a South Korean firm established in 2006, specializes in creating immunotherapeutic vaccines designed to combat various cancers and infectious ailments. Their pipeline includes BVAC-C, which targets cervical, head and neck, anal, ...